Vevorisertib trihydrochloride

Modify Date: 2025-08-22 18:36:28

Vevorisertib trihydrochloride Structure
Vevorisertib trihydrochloride structure
Common Name Vevorisertib trihydrochloride
CAS Number 1416775-08-0 Molecular Weight 696.11
Density N/A Boiling Point N/A
Molecular Formula C35H41Cl3N8O Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Vevorisertib trihydrochloride


Vevorisertib (ARQ 751) (trihydrochloride) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib (trihydrochloride), as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations[1][2][3][4].

 Names

Name Vevorisertib trihydrochloride

 Vevorisertib trihydrochloride Biological Activity

Description Vevorisertib (ARQ 751) (trihydrochloride) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib (trihydrochloride), as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations[1][2][3][4].
Related Catalog
Target

Akt1:0.55 nM (IC50)

Akt2:0.81 nM (IC50)

Akt3:1.31 nM (IC50)

In Vitro Vevorisertib binds to wild-type AKT1 and mutant AKT1-E17K with Kd of 1.2 nM and 8.6 nM, respectively, and suppresses pAKT(S473) in 293T cells transiently transfected with AKT1-E17K[4].
In Vivo Vevorisertib (10~120 mg/kg) exerts dose-dependent anti-tumor activity in an AKT1-E17K mutant endometrial patient-derived xenograft (PDX) model. Vevorisertib shows a plasma half-life of 4 to 5 hours and no tissue accumulation[4].
References

[1]. [1]. Vevorisertib (ARQ 751) (4440-001) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations.

[2]. [2]. ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

[3]. [3]. Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751

[4]. [4]. Abstract 374: In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitor

 Chemical & Physical Properties

Molecular Formula C35H41Cl3N8O
Molecular Weight 696.11
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here


Get all suppliers and price by the below link:

Vevorisertib trihydrochloride suppliers

Vevorisertib trihydrochloride price

Related Compounds: More...
Vevorisertib
1416775-46-6
Tazemetostat trihydrochloride
1403255-00-4
(3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4S,6R)-2-amino-4-hydroxy-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide,trihydrochloride
39750-31-7
Volasertib trihydrochloride
946161-17-7
Zosuquidar trihydrochloride
167465-36-3
LY2409881 trihydrochloride
946518-60-1
ARN5187 trihydrochloride
1700693-96-4
Tanuxiciclib trihydrochloride
1983984-11-7
Chitotriose trihydrochloride
117436-78-9
(3R)-3-({1-[({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)methyl]cyclobutyl}formamido)-4-methylpentanoic acid
2171270-01-0
(3R)-3-{2-[1-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)cyclobutyl]acetamido}-4-methylpentanoic acid
2171211-77-9
(1RS,5SR)-5-[(3S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]cyclohex-3-ene-1-carboxylic acid
2227786-24-3
4-[(3S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]-3,3-dimethylbutanoic acid
2171169-62-1
2-cyclobutyl-2-{2-[3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)cyclopentyl]acetamido}acetic acid
2171735-18-3
2-cyclobutyl-2-(2-{[2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)ethyl]sulfanyl}acetamido)acetic acid
2171584-22-6
4-[2-cyclopropyl-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)acetamido]-2-hydroxybenzoic acid
2171610-83-4
3-[2-cyclopropyl-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)acetamido]-4-hydroxybenzoic acid
2171590-35-3
(3R)-3-[(3S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]-4-methylpentanoic acid
2171270-09-8
(3S)-3-[(3S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]butanoic acid
2171188-06-8